Novartis’ Pluvicto Approved by FDA for Treatment of Advanced Prostate Cancer

FDA has approved Novartis’ targeted radioligand therapy Pluvicto for the treatment of progressive PSMA-positive metastatic castration-resistant prostate cancer.